<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793568</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0082</org_study_id>
    <nct_id>NCT04793568</nct_id>
  </id_info>
  <brief_title>Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study</brief_title>
  <acronym>PREV-HAP</acronym>
  <official_title>Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREV-HAP study is part of a larger project entitled 'Host-targeted Approaches for the&#xD;
      Prevention and the treatment of Hospital-Acquired Pneumonia' (HAP2), funded by the European&#xD;
      Union's H2020 research and innovation programme under grant agreement N°847782. HAP2 aims to&#xD;
      develop stratified host-directed drugs and biomarkers to enhance the prevention and the&#xD;
      treatment of HAP and develop precision medicine in infectious diseases. Its ambition is to&#xD;
      revolutionize the management of HAP: capitalising on the novel concept of critical-illness&#xD;
      related immunosuppression altering the host-pathogens interactions, the aim is to propose a&#xD;
      complete reappraisal of the physiopathology of HAP based on the concept of respiratory&#xD;
      dysbiosis.&#xD;
&#xD;
      The main hypothesis of the PREV-HAP study is that human recombinant Interferon gamma 1b&#xD;
      (rHuIFN-γ, Imukin) treatment can restore immunity in critically ill patients and prevent&#xD;
      Hospital-Acquired Pneumonia.&#xD;
&#xD;
      The hypothesesis is that the in vivo investigations of the host-pathogens interactions can be&#xD;
      used for the stratification of patients into high/low risk and responders/non-responders to&#xD;
      host-targeted prevention of hospital-acquired infections.&#xD;
&#xD;
      The involvement of a state of critical-illness related immunosuppression in the&#xD;
      susceptibility to hospital-acquired pneumonia is widely accepted, and an emerging trend is&#xD;
      that the development of drugs for the treatment of this acquired immunosuppression will&#xD;
      prevent infection and enhance outcomes of hospitalized patients.&#xD;
&#xD;
      It has been demonstrated that the productions of IFN-γ by immune cells are decreased in&#xD;
      critically ill patients, and that these defects are associated with the susceptibility to&#xD;
      HAP. rHuIFN-γ has neither been tested nor is recommended as adjunctive treatment of patients&#xD;
      with HAP. Based on these specific factors identified in the host response, it is proposed in&#xD;
      this study to use rHuIFN-γ as novel preventive approach for HAP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 adult patients hospitalized in intensive care units, under mechanical ventilation in&#xD;
      three European countries will be included in the trial, and will be randomized in 2 arms :&#xD;
&#xD;
      Arm 1 (rHu-IFNγ):&#xD;
&#xD;
      • Recombinant Interferon gamma 1b (IMUKIN®, from Clinigen®): 100 µg/0,5ml subcutaneous&#xD;
      injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h),&#xD;
&#xD;
      Arm 2 (Placebo):&#xD;
&#xD;
      • Recombinant Interferon gamma 1b placebo: 5 subcutaneous injections from day 1 to day 9&#xD;
      (i.e. 1 injection of 0,5ml every 48h).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the efficiency of rHuIFN-γ for the prevention of hospital-acquired pneumonia</measure>
    <time_frame>Day 28</time_frame>
    <description>Rate of the composite outcome at day 28 made of at least one item among the following: all cause mortality and/or hospital-acquired pneumonia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality [efficiency of rHu-IFN-γ, on pneumonia-associated morbidity and mortality reduction]</measure>
    <time_frame>Day 28 and Day 90</time_frame>
    <description>Rate of all-cause mortality at D28 and D90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HAP [efficiency]</measure>
    <time_frame>Day 28</time_frame>
    <description>Rate of HAP at D28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial ecology of the 1st episode of HAP [efficiency]</measure>
    <time_frame>Day 28</time_frame>
    <description>Bacterial ecology of the 1st episode of HAP (respiratory fluids)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ventilator-associated tracheobronchitis [efficiency]</measure>
    <time_frame>Day 28</time_frame>
    <description>Rate of ventilator-associated tracheobronchitis at D28 defined as at least two of the following criteria: body temperature &gt;38°C; leukocytosis&gt;12000 cells/mL, leucopenia &lt;4000 cells/mL, or purulent pulmonary secretions and a positive culture of a respiratory tract samples, without appearance of a new infiltrate or change in an existing infiltrate on chest radiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Acute Respiratory Distress Syndrome [efficiency]</measure>
    <time_frame>Day 28</time_frame>
    <description>Acute Respiratory Distress Syndrome within 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antimicrobial therapy [efficiency]</measure>
    <time_frame>Day 28</time_frame>
    <description>Duration of antimicrobial therapy at D28, antibiotic free days at D28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation [efficiency]</measure>
    <time_frame>Day 90</time_frame>
    <description>Duration of mechanical ventilation at D90, mechanical ventilation free days at D90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU hospitalization [efficiency]</measure>
    <time_frame>Day 90</time_frame>
    <description>Duration of ICU hospitalization at D90, Duration of hospitalization at D90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of SAEs and SUSARs [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of serious adverse effects and suspected unexpected serious adverse reaction (SUSAR) at D15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of leukocytosis [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of leukocytosis at D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of neutropenia [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of neutropenia at D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of lymphopenia [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of lymphopenia at D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombopenia [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of thrombopenia at D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of liver cytolysis [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of liver cytolysis (Increases in AST and/or ALT) at D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pancreatitis [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of pancreatitis (Increase in Lipase) at D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with episode of fever [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of patients with episode of fever (T° &gt; 38.3°C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with episode of headache [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of patients with episode of headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with episode of nausea [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of patients with episode of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of allergic reaction [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of major allergic reaction at D15 defined as systemic epidermic reaction, anaphylactic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of injection site reaction [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Occurence of injection site reaction at D15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of myalgia [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of myalgia at D15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of arthralgia [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of arthralgia at D15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of back pain [tolerance]</measure>
    <time_frame>Day 15</time_frame>
    <description>Rate of back pain at D15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic efficiency of rHu-IFN-γ in the prevention of pneumonia</measure>
    <time_frame>Day 90</time_frame>
    <description>Economic endpoint at 3 months: Incremental cost effectiveness ratio (ICER). Analysis using QALYs (Quality-Adjusted Life-Years) as a measure of effectiveness. QALYs are a measure of effectiveness specifically designed for economic evaluations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the suitability of rHu-IFN-γ from the patients' and relatives' perspectives using The Short Form (36) Health Survey</measure>
    <time_frame>Day 90</time_frame>
    <description>Changes in health-related quality of life (HRQoL) from one (M1) to three months (M3) after randomization measured with the Short Form (SF)-36 scale validated in French, Greek, and Spanish he SF-36 is a 36-item self-report questionnaire with 8 domains = Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health).The scores of each domain range from 0 to 100, a higher score indicating a better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the suitability of rHu-IFN-γ from the patients' and relatives' perspectives using the Hospital Anxiety and Depression scale (HADS)</measure>
    <time_frame>Day 90</time_frame>
    <description>Changes in anxiety and depression from M1 to M3 measured with the HADS scale validated in French, Greek, and Spanish. The HADS is a 14-item self-report questionnaire with 2 domains (anxietyand depression).&#xD;
The scores for anxiety and depression range from 0 (no symptoms) to 21 (significant number of symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the suitability of rHu-IFN-γ from the patients' and relatives' perspectives using Satisfaction With Life Scale (SWLS)</measure>
    <time_frame>Day 90</time_frame>
    <description>Changes in subjective well-being from M1 to M3 measured with the Satisfaction With Life Scale (SWLS) validated in French, Greek, and Spanish. The SWLS is a 5-item self-report questionnaire. The response scores to the five items are added together to provide a total score ranging from 5 (worst satisfaction level) to 35 (best level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the acceptability of rHu-IFN-γ from the patients' and relatives' perspectives</measure>
    <time_frame>Day 90</time_frame>
    <description>Adaptation of the patients to their health state and its evolution from M1 to M3 using differential item functioning and response shift analyses for HRQoL, anxiety and depression. Change in the meaning of patients' self-evaluation between groups (DIF) and over time (response shift) will be inferred by the change in the items' parameters of the Partial Credit Models.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Critically Ill Patients</condition>
  <arm_group>
    <arm_group_label>Recombinant Interferon gamma 1b (IMUKIN®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombinant Interferon gamma 1b placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Interferon gamma 1b (IMUKIN®)</intervention_name>
    <description>100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)</description>
    <arm_group_label>Recombinant Interferon gamma 1b (IMUKIN®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Interferon gamma 1b placebo</intervention_name>
    <description>5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).</description>
    <arm_group_label>Recombinant Interferon gamma 1b placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18yr to 85yr).&#xD;
&#xD;
          -  Hospitalized in intensive care unit for less than 48 hours.&#xD;
&#xD;
          -  Receiving invasive mechanical ventilation at the time of inclusion.&#xD;
&#xD;
          -  One or more acute organ failure at the time of inclusion among: neurological (Glasgow&#xD;
             coma scale &lt;13 before sedation), hemodynamic (norepinephrine, epinephrine, or any&#xD;
             other vasopressor at a dose of ≥ 0.1 μg per kilogram of body weight per minute or ≥0.5&#xD;
             mg per hour for at least 6 hours), respiratory (PaO2 / FiO2&lt; 200) and/or renal&#xD;
             (creatininemia &gt; 2 fold higher than the basal value and/or oliguria &lt; 0.5 mL/kg/hour&#xD;
             for at less 12 hours).&#xD;
&#xD;
          -  Informed consent from a legal representative, or emergency procedure (when possible&#xD;
             according to national regulation, see below). As is not possible to obtain the patient&#xD;
             consent prior the inclusion (comatose patients), patient consent for the study&#xD;
             continuation will be obtained as soon as deemed possible.&#xD;
&#xD;
          -  Person insured under a health insurance scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women (serum or urine test), breastfeeding women&#xD;
&#xD;
          -  Patient under legal protection (incl. under guardianship or trusteeship)&#xD;
&#xD;
          -  Hypersensitivity to the active substance (interferon gamma-1b) or known&#xD;
             hypersensitivity to related products, such as another interferon, or to any of the&#xD;
             following excipients: Mannitol, Disodium succinate hexahydrate, Succinic acid,&#xD;
             Polysorbate 20&#xD;
&#xD;
          -  Severe hepatic insufficiency ( Child Pugh score B or C)&#xD;
&#xD;
          -  Liver cytolysis with hepatic enzymes (AST and/or ALT) &gt; 5N&#xD;
&#xD;
          -  Severe chronic renal insufficiency (MDRD Creatinine Clearance &lt; 10 ml/min/1.73m2)&#xD;
&#xD;
          -  Immunosuppression (hematologic cancer, aplasia, chemotherapy/radiotherapy for cancer&#xD;
             within 3 months prior to the inclusion, known infection Human immunodeficiency virus,&#xD;
             concomitant use of any anti-graft rejection drug).&#xD;
&#xD;
          -  Coma after resuscitated cardiac arrest&#xD;
&#xD;
          -  Cervical spinal cord injury&#xD;
&#xD;
          -  Participation to a drug interventional study within 1 month prior to the inclusion&#xD;
&#xD;
          -  Hospital-acquired pneumonia before inclusion in the study during the current&#xD;
             hospitalization.&#xD;
&#xD;
          -  Sustained hyperlactatemia &gt; 5 mmol/L.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine Roquilly</last_name>
    <phone>0033253482230</phone>
    <email>antoine.roquilly@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigismond LASOCKI</last_name>
      <email>sigismond.lasocki@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Argenteuil Hospital</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetan Plantefeve</last_name>
      <email>gaetan.plantefeve@ch-argenteuil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Huet</last_name>
      <email>olivier.huet@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaujon University Hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Weiss</last_name>
      <email>emmanuel.weiss@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno François</last_name>
      <email>bruno.francois@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Roquilly</last_name>
      <email>antoine.roquilly@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Roquilly</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël Cinotti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Seguin</last_name>
      <email>philippe.seguin@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aghioi Anargyroi General Oncology Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georgios FILDISIS</last_name>
      <email>gfildis@nurs.uoa.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Athen</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Apostolos ARMAGANIDIS</last_name>
      <email>aarmag@med.uoa.gr</email>
    </contact>
    <investigator>
      <last_name>Apostolos ARMAGANIDIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Despoina KOULENTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitrios GEORGOPOULOS</last_name>
      <email>georgop@med.uoc.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vasileios KOULOURAS</last_name>
      <email>vpkoulouras@yahoo.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Epameinondas ZAKYNTHINOS</last_name>
      <email>ezakynth@med.uth.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koutlimbaneio &amp; Triantafylleio General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Apostolos KOMNOS</last_name>
      <email>komnosapo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoni TORRES</last_name>
      <email>ATORRES@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricard FERRER</last_name>
      <email>r.ferrer@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús CABALLERO</last_name>
      <email>jcaballero.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel SANCHEZ</last_name>
      <email>miguelsanchez.hcsc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Son Llátzer</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcio BORGES</last_name>
      <email>mborges1967@yahoo.es</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

